142 related articles for article (PubMed ID: 22608846)
1. Killed but metabolically active vaccines.
Dubensky TW; Skoble J; Lauer P; Brockstedt DG
Curr Opin Biotechnol; 2012 Dec; 23(6):917-23. PubMed ID: 22608846
[TBL] [Abstract][Full Text] [Related]
2. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
Brockstedt DG; Bahjat KS; Giedlin MA; Liu W; Leong M; Luckett W; Gao Y; Schnupf P; Kapadia D; Castro G; Lim JY; Sampson-Johannes A; Herskovits AA; Stassinopoulos A; Bouwer HG; Hearst JE; Portnoy DA; Cook DN; Dubensky TW
Nat Med; 2005 Aug; 11(8):853-60. PubMed ID: 16041382
[TBL] [Abstract][Full Text] [Related]
3. Generation of killed but metabolically active (KBMA) Edwardsiella tarda and evaluation of its potential as a protective vaccine.
Choi SH; Kim MS; Kim KH
Fish Shellfish Immunol; 2015 Aug; 45(2):889-94. PubMed ID: 26074095
[TBL] [Abstract][Full Text] [Related]
4. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
[TBL] [Abstract][Full Text] [Related]
5. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector.
Lankowski AJ; Hohmann EL
J Infect Dis; 2007 Apr; 195(8):1203-11. PubMed ID: 17357059
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.
Singh R; Wallecha A
Hum Vaccin; 2011 May; 7(5):497-505. PubMed ID: 21422819
[TBL] [Abstract][Full Text] [Related]
7. Live-attenuated Listeria-based immunotherapy.
Rothman J; Paterson Y
Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
[TBL] [Abstract][Full Text] [Related]
8. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
[TBL] [Abstract][Full Text] [Related]
9. [Development of a killed but metabolically active anthracis vaccine candidate strain].
Shen F; Yuan S; Zhan D; Wang Y; Ren M; Tao H; Wang P; Wang L; Chen D; Liu C
Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):781-9. PubMed ID: 21845845
[TBL] [Abstract][Full Text] [Related]
10. Vaccines against leishmaniasis.
Modabber F
Ann Trop Med Parasitol; 1995 Dec; 89 Suppl 1():83-8. PubMed ID: 8745930
[TBL] [Abstract][Full Text] [Related]
11. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Brockstedt DG; Dubensky TW
Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
13. Listeria as a vaccine vector.
Bruhn KW; Craft N; Miller JF
Microbes Infect; 2007 Aug; 9(10):1226-35. PubMed ID: 17719258
[TBL] [Abstract][Full Text] [Related]
14. Prospects and progress of Listeria-based cancer vaccines.
Bolhassani A; Naderi N; Soleymani S
Expert Opin Biol Ther; 2017 Nov; 17(11):1389-1400. PubMed ID: 28823183
[TBL] [Abstract][Full Text] [Related]
15. [Listeria monocytogenes: a dangerous pathogen used as a vector for the new generation of vaccines].
Tkachuk MV; Iarovinskiĭ FO; Tonevitskiĭ AG
Vopr Med Khim; 2000; 46(3):256-64. PubMed ID: 11033885
[TBL] [Abstract][Full Text] [Related]
16. Characterization of killed but metabolically active uropathogenic Escherichia coli strain as possible vaccine candidate for urinary tract infection.
Jalili Z; Saleh M; Bouzari S; Pooya M
Microb Pathog; 2018 Sep; 122():184-190. PubMed ID: 29935339
[TBL] [Abstract][Full Text] [Related]
17. Progress on vaccines against parasites.
Engers HD; Bergquist R; Modabber F
Dev Biol Stand; 1996; 87():73-84. PubMed ID: 8854004
[TBL] [Abstract][Full Text] [Related]
18. [Approaches and problems in vaccine development against leishmaniasis].
Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD
Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
[TBL] [Abstract][Full Text] [Related]
20. [New technologies for vaccine development].
Leclerc C
Med Sci (Paris); 2007 Apr; 23(4):386-90. PubMed ID: 17433228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
